Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies
Purpose. Mucopolysaccharidoses (MPS) are group of inherited lysosomal storage diseases caused by mutations of enzymes involved in catalyzing different glycosaminoglycans (GAGs). MPS I and MPS II exhibit both somatic and neurological symptoms with a relatively high disease incidence. Hematopoietic st...
Main Authors: | Haiyan Nan, Chanbum Park, Sungho Maeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2020/2408402 |
Similar Items
-
Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS
by: Chloe L. Christensen, et al.
Published: (2019-06-01) -
Glaucoma in mucopolysaccharidoses
by: Weijing Kong, et al.
Published: (2021-07-01) -
Diagnosis of Mucopolysaccharidoses
by: Francyne Kubaski, et al.
Published: (2020-03-01) -
ENT and mucopolysaccharidoses
by: Pier Marco Bianchi, et al.
Published: (2018-11-01) -
Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses
by: Yuji Sato, et al.
Published: (2020-01-01)